Anavex Life Sciences Corp.
AVXL
Positions held
Your positionsAVXL isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $142.75M | Enterprise value | $24.43M | Trailing P/E | — | Forward P/E | -2.80 |
| PEG | — | Price / book | 1.27 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -12.8% | ROA | -9.7% | Debt / equity | — |
| Current ratio | 15.62 | Free cash flow | -$27.06M | Analyst recommendation | none | Mean target | — |
| 52w high | $9.53 | 52w low | $1.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | $7.8M | -$5.3M | -$5.7M | -$9.8M | -$13.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | $6.8M | -$6.5M | -$6.8M | -$11.5M | -$14.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$51.4M | -$52.8M | -$55.7M | -$51.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-24 · Anavex Life Sciences Shareholders Elect All Six Board Nominees
2026-09-24 · Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
2026-09-18 · PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
2026-09-10 · PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
2026-09-09 · PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)
2026-09-08 · Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
2026-09-03 · PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
2026-09-02 · Anavex Life Sciences Regains Nasdaq Compliance After Filing Quarterly Reports
2026-09-02 · Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Price (daily)
Full chart · RSI · MACD · patterns